AssayIndex
Hypothalamic and posterior-pituitary hormones

Triptorelin

D-Trp6-LHRH · Decapeptyl · Trelstar · C64H82N18O13 · monoisotopic 1310.6248 Da. The index holds 24 assay reports on this compound across 4 batches from 4 suppliers.

24 reports4 batchesmedian 99.41 %index spec 98.5 %
Section 1

Analytical fingerprint

Hand-authored chemistry. These properties describe the substance and do not change when a record is added.

Triptorelin is the D-Trp6 analogue and the [L-Trp6] diastereomer — which is, functionally, a much weaker peptide — is mass-identical and only 0.20 min away. This is the archetype of the index's position that a purity number without a stated gradient length is uninterpretable: on a 12-min gradient the diastereomer is inside the main peak.

Molecular formula
C64H82N18O13
Monoisotopic mass
1310.6248Da
Average mass
1311.45Da
Residues
10
Nominal retention (RG-2, 30 min)
9.72min
Retention window
0.25min
Counter-ion as usually shipped
acetate
Typical label claims
2 mg · 5 mg · 10 mg
Analytical difficulty (index scale)
0.90 — straightforward
Purity is a defined quantity
YES
Section 2

Representative chromatogram

Drawn from this page's own medians. Not a scan, not an illustration, and not any single report.

027625523828511047 Triptorelin9.72 min · 99.41 % 9.52 same trace · ×200 vertical expansion, baseline-corrected · main peak off-scale reporting threshold 0.05 % area 05101520253035 Retention time (min) Response (mAU)
Figure 1. A representative Triptorelin trace on the index reference method RG-2, constructed from this page's own numbers: the main peak carries the index median purity of 99.41 % area at the nominal retention time of 9.72 min, and each impurity peak carries the median area the index has observed for that named species at its characteristic retention offset. It is not a scan of any single report — every individual record's own chromatogram is on its own page. The lower panel is the same trace at a stated vertical expansion, baseline-corrected, so the impurities are visible; the main peak runs off-scale there by design. Baseline noise is seeded from the compound slug.
Section 3

What the index has observed

Arithmetic over the 24 records the index holds. Aggregates on this page are computed over the records the index holds, which are not a random sample of the material on the market. Lots that get tested are lots someone chose to test. Read every figure here as a description of this dataset rather than as an estimate of a population.

Median purity 99.41% n=24
Interquartile range 0.63pp n=24
Minimum 98.27% n=24
Maximum 99.93% n=24
Pass rate vs spec 91.7% n=24
Median recovery vs claim 99.1% n=11
Median water 4.73% n=24
Median |mass error| 3.7ppm n=19
036992.093.094.095.096.097.098.099.0100.092.00–92.25 %: n=092.25–92.50 %: n=092.50–92.75 %: n=092.75–93.00 %: n=093.00–93.25 %: n=093.25–93.50 %: n=093.50–93.75 %: n=093.75–94.00 %: n=094.00–94.25 %: n=094.25–94.50 %: n=094.50–94.75 %: n=094.75–95.00 %: n=095.00–95.25 %: n=095.25–95.50 %: n=095.50–95.75 %: n=095.75–96.00 %: n=096.00–96.25 %: n=096.25–96.50 %: n=096.50–96.75 %: n=096.75–97.00 %: n=097.00–97.25 %: n=097.25–97.50 %: n=097.50–97.75 %: n=097.75–98.00 %: n=098.00–98.25 %: n=098.25–98.50 %: n=298.50–98.75 %: n=198.75–99.00 %: n=599.00–99.25 %: n=199.25–99.50 %: n=1099.50–99.75 %: n=299.75–100.00 %: n=3median 99.41 Purity (% area) Reports
Figure 2. Purity distribution across all 24 Triptorelin records. Dashed line is this compound's median (99.41 %); the solid vertical is the index acceptance specification for the hypothalamic and posterior-pituitary hormones class (98.5 %). Domain is fixed at 92–100 % on every purity histogram on this site so that compounds can be compared by eye — a wide distribution here is a hard compound, a narrow one is an easy one, and neither is a statement about the suppliers.
Section 4

By supplier

Suppliers with fewer than two purity records on this compound are omitted from the figure rather than drawn as a line. The full table, including the thin cells, is on the by-supplier page.

98.198.598.899.199.499.7100.1HYBHYB: Q1 99.40, median 99.46, Q3 99.52, n=12outlier 99.93outlier 99.93n=12SGNSGN: Q1 98.59, median 98.80, Q3 98.89, n=10outlier 99.43outlier 99.49n=10 Purity (% area)
Figure 3. Triptorelin purity by supplier, ordered by coverage. The vertical line is the index acceptance specification. Boxes that overlap are suppliers this dataset cannot separate, and most of them overlap.

Full per-supplier table with n= caveats →

Section 5

Characteristic impurities and degradants

The left three columns are authored chemistry — what this molecule characteristically carries and where it elutes. The right three are what the index has actually reported.

Named speciesΔRT (min, RG-2)Δ mass (Da)Seen inMedian % areaMax % area
[L-Trp6]-diastereomer (gonadorelin analogue)-0.20mass-identical96%0.191.09
oxidised Trp (+16 Da)-0.34+15.99596%0.080.55
ring-opened pGlu (+18 Da)-0.48+18.01192%0.160.84
des-Gly10-NH2 (−74 Da)-0.26-74.04892%0.080.24

Degradation pathways

  • epimerisation at Trp6
  • pGlu ring opening

Full impurity profile, with what each named species implies about the synthesis →

Section 6

Clinical context

Included because it is routinely misapplied. Trial data describes a licensed medicinal product manufactured under a marketing authorisation, and it does not transfer to research-grade material of unknown provenance.

Triptorelin has been approved since the 1980s for prostate cancer, endometriosis and central precocious puberty.

Section 7

Quarterly coverage

QuarterReportsMedian purityRange
2024-Q10n<3—
2024-Q20n<3—
2024-Q30n<3—
2024-Q41n<3—
2025-Q10n<3—
2025-Q21098.8098.27–99.49
2025-Q30n<3—
2025-Q40n<3—
2026-Q11299.4699.22–99.93
2026-Q20n<3—
2026-Q31n<3—

Quarter-by-quarter detail →

Section 8

Most recent records

The 25 most recent Triptorelin records of 24.
ReportSupplierLotLabQuarterPurity %Water %Recovery %ProvenanceFlagsResult
AX-2026-041477QSCQSC-2607-C5749Nordanalyt2026-Q399.533.42—Buyer-sourced0PASS
AX-2026-042060HYBHYB-2512-B7307Janoshik2026-Q199.463.8694.9Buyer-sourced0PASS
AX-2026-042068HYBHYB-2512-B7307Janoshik2026-Q199.384.4088.8Buyer-sourced1MARGINAL
AX-2026-042063HYBHYB-2512-B7307PeptideMeter2026-Q199.934.2899.1Supplier-supplied0PASS
AX-2026-042062HYBHYB-2512-B7307PeptideMeter2026-Q199.934.16—Buyer-sourced0PASS
AX-2026-042061HYBHYB-2512-B7307Medutest2026-Q199.224.88100.4Laboratory-retained0PASS
AX-2026-042064HYBHYB-2512-B7307Medutest2026-Q199.464.1890.0Buyer-sourced1FAIL
AX-2026-042065HYBHYB-2512-B7307Medutest2026-Q199.404.83—Buyer-sourced1MARGINAL
AX-2026-042069HYBHYB-2512-B7307Janoshik2026-Q199.333.89—Buyer-sourced0PASS
AX-2026-042070HYBHYB-2512-B7307Janoshik2026-Q199.414.43—Buyer-sourced0PASS
AX-2026-042071HYBHYB-2512-B7307PeptideMeter2026-Q199.494.78106.6Buyer-sourced0PASS
AX-2026-042067HYBHYB-2512-B7307Medutest2026-Q199.604.31105.3Buyer-sourced0PASS
AX-2026-042066HYBHYB-2512-B7307Medutest2026-Q199.484.68—Buyer-sourced1FAIL
AX-2025-020735SGNSGN-2504-A9334Janoshik2025-Q298.875.88—Buyer-sourced0PASS
AX-2025-020742SGNSGN-2504-A9334Medutest2025-Q298.544.2490.1Buyer-sourced1FAIL
AX-2025-020743SGNSGN-2504-A9334Janoshik2025-Q299.434.95105.6Supplier-supplied0PASS
AX-2025-020734SGNSGN-2504-A9334Medutest2025-Q298.814.98103.8Buyer-sourced0PASS
AX-2025-020737SGNSGN-2504-A9334Janoshik2025-Q298.795.15—Buyer-sourced0PASS
AX-2025-020740SGNSGN-2504-A9334Janoshik2025-Q298.754.93—Buyer-sourced0PASS
AX-2025-020736SGNSGN-2504-A9334Nordanalyt2025-Q299.494.46—Supplier-supplied0PASS
AX-2025-020741SGNSGN-2504-A9334VendorInvestigate2025-Q298.485.10—Buyer-sourced0FAIL
AX-2025-020739SGNSGN-2504-A9334Medutest2025-Q298.905.1592.8Supplier-supplied1FAIL
AX-2025-020738SGNSGN-2504-A9334Janoshik2025-Q298.275.18—Buyer-sourced0FAIL
AX-2024-004396ASYASY-{CAT}-1986Janoshik2024-Q499.935.47—Buyer-sourced0PASS